PL2528897T3 - Di-podstawione pochodne pirydyny jako leki przeciwnowotworowe - Google Patents
Di-podstawione pochodne pirydyny jako leki przeciwnowotworoweInfo
- Publication number
- PL2528897T3 PL2528897T3 PL11705048T PL11705048T PL2528897T3 PL 2528897 T3 PL2528897 T3 PL 2528897T3 PL 11705048 T PL11705048 T PL 11705048T PL 11705048 T PL11705048 T PL 11705048T PL 2528897 T3 PL2528897 T3 PL 2528897T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer drugs
- pyridine derivatives
- substituted pyridine
- substituted
- drugs
- Prior art date
Links
- -1 DI-SUBSTITUTED PYRIDINE Chemical class 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940041181 antineoplastic drug Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29963110P | 2010-01-29 | 2010-01-29 | |
| US35972910P | 2010-06-29 | 2010-06-29 | |
| PCT/JP2011/052302 WO2011093524A1 (en) | 2010-01-29 | 2011-01-28 | Di - substituted pyridine derivatives as anticancers |
| EP11705048.4A EP2528897B9 (en) | 2010-01-29 | 2011-01-28 | Di-substituted pyridine derivatives as anticancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2528897T3 true PL2528897T3 (pl) | 2015-03-31 |
Family
ID=43797869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11705048T PL2528897T3 (pl) | 2010-01-29 | 2011-01-28 | Di-podstawione pochodne pirydyny jako leki przeciwnowotworowe |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8722663B2 (pl) |
| EP (1) | EP2528897B9 (pl) |
| JP (1) | JP5335932B2 (pl) |
| KR (1) | KR101411030B1 (pl) |
| CN (1) | CN102791690B (pl) |
| AR (1) | AR080057A1 (pl) |
| AU (1) | AU2011211306B2 (pl) |
| CA (1) | CA2788073A1 (pl) |
| CO (1) | CO6561817A2 (pl) |
| DK (1) | DK2528897T3 (pl) |
| EA (1) | EA026042B1 (pl) |
| ES (1) | ES2521016T3 (pl) |
| HR (1) | HRP20141190T1 (pl) |
| IL (1) | IL221146A (pl) |
| MX (1) | MX2012008391A (pl) |
| MY (1) | MY160875A (pl) |
| NZ (1) | NZ601794A (pl) |
| PH (1) | PH12012501532A1 (pl) |
| PL (1) | PL2528897T3 (pl) |
| PT (1) | PT2528897E (pl) |
| RS (1) | RS53705B1 (pl) |
| SG (1) | SG182663A1 (pl) |
| SI (1) | SI2528897T1 (pl) |
| SM (1) | SMT201500007B (pl) |
| TW (1) | TWI404713B (pl) |
| UA (1) | UA107692C2 (pl) |
| WO (1) | WO2011093524A1 (pl) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013047223A (ja) * | 2011-07-28 | 2013-03-07 | Otsuka Pharmaceut Co Ltd | 医薬 |
| MX394360B (es) | 2013-03-14 | 2025-03-24 | Sumitomo Pharma Oncology Inc | Inhibidores de jak2 y alk2 y metodos para su uso. |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| WO2015027067A2 (en) * | 2013-08-23 | 2015-02-26 | Virginia Commonwealth University | Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| JP2017528498A (ja) * | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| WO2018064510A1 (en) | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3523289A1 (en) | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| KR20210003780A (ko) | 2018-04-05 | 2021-01-12 | 스미토모 다이니폰 파마 온콜로지, 인크. | Axl 키나제 억제제 및 그의 용도 |
| AU2019310590A1 (en) | 2018-07-26 | 2021-01-14 | Sumitomo Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| MX2021000887A (es) | 2018-08-01 | 2021-03-31 | Araxes Pharma Llc | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. |
| CN112812781B (zh) * | 2021-01-21 | 2023-09-29 | 西安瑞联新材料股份有限公司 | 一种基于双哌嗪类苯并噁唑液晶化合物及其制备方法 |
| CN116903587B (zh) * | 2023-06-01 | 2024-03-22 | 三峡大学 | 一种角鲨烯环氧酶抑制剂及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63301880A (ja) * | 1985-09-03 | 1988-12-08 | Otsuka Pharmaceut Co Ltd | ５−フルオロウラシル誘導体 |
| AR015733A1 (es) * | 1998-03-25 | 2001-05-16 | Otsuka Pharma Co Ltd | DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO. |
| US6262088B1 (en) * | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
| JP2001089450A (ja) * | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ピリジン誘導体含有医薬製剤 |
| JP2001089412A (ja) * | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
| JP2002226429A (ja) * | 2001-02-06 | 2002-08-14 | Fuji Photo Film Co Ltd | アクリル酸エステル化合物の製造方法 |
| GB0224917D0 (en) * | 2002-10-25 | 2002-12-04 | Novartis Ag | Organic compounds |
| ZA200700811B (en) * | 2004-08-06 | 2008-10-29 | Otsuka Pharma Co Ltd | Aromatic compound |
| CN101321529B (zh) * | 2005-12-05 | 2012-09-05 | 大塚制药株式会社 | 作为抗肿瘤剂的二芳基醚衍生物 |
| JP5142513B2 (ja) * | 2005-12-05 | 2013-02-13 | 大塚製薬株式会社 | 医薬 |
| UA95978C2 (ru) | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
| US20100136509A1 (en) | 2007-07-02 | 2010-06-03 | Alden Mejer | System and method for clinical trial investigator meeting delivery and training including dynamic media enrichment |
| TWI440638B (zh) | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | 雜環化合物及其藥學組成物 |
| DE202009007345U1 (de) | 2009-05-22 | 2009-09-10 | Schebo (R) . Biotech Ag | Neue Pharmazeutika und Arzneimittelzubereitungen |
-
2011
- 2011-01-28 HR HRP20141190AT patent/HRP20141190T1/hr unknown
- 2011-01-28 PL PL11705048T patent/PL2528897T3/pl unknown
- 2011-01-28 US US13/318,053 patent/US8722663B2/en not_active Expired - Fee Related
- 2011-01-28 SG SG2012054243A patent/SG182663A1/en unknown
- 2011-01-28 ES ES11705048.4T patent/ES2521016T3/es active Active
- 2011-01-28 EA EA201290720A patent/EA026042B1/ru not_active IP Right Cessation
- 2011-01-28 CN CN201180007162.2A patent/CN102791690B/zh not_active Expired - Fee Related
- 2011-01-28 JP JP2011545133A patent/JP5335932B2/ja not_active Expired - Fee Related
- 2011-01-28 NZ NZ601794A patent/NZ601794A/en not_active IP Right Cessation
- 2011-01-28 EP EP11705048.4A patent/EP2528897B9/en active Active
- 2011-01-28 WO PCT/JP2011/052302 patent/WO2011093524A1/en not_active Ceased
- 2011-01-28 SI SI201130359T patent/SI2528897T1/sl unknown
- 2011-01-28 RS RS20140688A patent/RS53705B1/sr unknown
- 2011-01-28 CA CA2788073A patent/CA2788073A1/en not_active Abandoned
- 2011-01-28 AR ARP110100297A patent/AR080057A1/es unknown
- 2011-01-28 MX MX2012008391A patent/MX2012008391A/es active IP Right Grant
- 2011-01-28 TW TW100103410A patent/TWI404713B/zh not_active IP Right Cessation
- 2011-01-28 PT PT117050484T patent/PT2528897E/pt unknown
- 2011-01-28 AU AU2011211306A patent/AU2011211306B2/en not_active Ceased
- 2011-01-28 DK DK11705048.4T patent/DK2528897T3/en active
- 2011-01-28 UA UAA201209216A patent/UA107692C2/uk unknown
- 2011-01-28 PH PH1/2012/501532A patent/PH12012501532A1/en unknown
- 2011-01-28 MY MYPI2012003367A patent/MY160875A/en unknown
- 2011-01-28 KR KR1020117025212A patent/KR101411030B1/ko not_active Expired - Fee Related
-
2012
- 2012-07-19 CO CO12121461A patent/CO6561817A2/es unknown
- 2012-07-26 IL IL221146A patent/IL221146A/en not_active IP Right Cessation
-
2015
- 2015-01-09 SM SM201500007T patent/SMT201500007B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2528897T3 (pl) | Di-podstawione pochodne pirydyny jako leki przeciwnowotworowe | |
| CY2022027I1 (el) | Παραγωγα βενζιμιδαζολο-προλινης | |
| PT2620436T (pt) | Profármaco de derivado de carbamoilo piridona policíclica substituída | |
| CO7071126A2 (es) | Derivados de piridona | |
| PT2684880T (pt) | Derivado de dispiropirrolidina | |
| PT2696848T (pt) | Nanossuspensões de fármaco liofilizadas | |
| IL245328A0 (en) | Pharmaceutical composition | |
| PT2906251T (pt) | Conjugados de pirrolobenzodiazepina-anticorpo anti-cd22 | |
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| PT2944633T (pt) | Derivado de piridina | |
| EP2709645A4 (en) | ENHANCED PEPTIDE PHARMACEUTICAL AGENTS | |
| ZA201503969B (en) | Novel pyridine derivatives | |
| IL230838A0 (en) | Pharmaceutical compositions | |
| BR112015002950A2 (pt) | novos derivados de bicíclico-piridina | |
| BR112014003441A2 (pt) | unidade de dobramento | |
| BR112014003440A2 (pt) | unidade de dobramento | |
| CO7020919A2 (es) | Derivados de tetrahidro-quinazolinona | |
| DK2343051T3 (da) | Anti-cancer formulering | |
| BR112014015885A2 (pt) | preparação farmacêutica | |
| CO6960557A2 (es) | Derivados de 2-yodo-imidazol | |
| BR112014009319A2 (pt) | compostos farmacêuticos | |
| EP2832355A4 (en) | CANCER AGENT | |
| EP2558094A4 (en) | pyridone derivatives | |
| EP2661173A4 (en) | ANTI CANCER THERAPY | |
| CO6852074A2 (es) | Novedosos derivados de ftalazinona-pirrolopirimidinacarboxamida |